Lorenzo Chiaverini

Dr. Lorenzo Chiaverini

University of Pisa, Pisa, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Lorenzo ChiaveriniLorenzo Chiaverini
Lorenzo Chiaverini
Alessandro PratesiAlessandro Pratesi
Alessandro Pratesi
Damiano CirriDamiano Cirri
Damiano Cirri
ANArianna Nardinocchi
Arianna Nardinocchi
Iogann TolbatovIogann Tolbatov
Iogann Tolbatov
DMDiego La Mendola
Diego La Mendola
Auranofin (AF, hereafter) is an orally administered chrysotherapeutic agent approved for the treatment of rheumatoid arthritis that is being repurposed for various indications including bacterial infections. Its likely mode of action involves the impairment of the TrxR system through the binding of the pharmacophoric cation [AuPEt3]+. Accordingly, a reliable strategy to expand the medicinal profile of AF is the replacement of the thiosugar moiety with different ligands. Herein, we aimed to prepare the AF analogue bearing the acetylcysteine ligand (AF-AcCys, hereafter) and characterize its anti-staphylococcal activity. Biological studies revealed that AF-AcCys retains an antibacterial effect superimposable with that of AF against Staphylococcus aureus, whereas it is about 20 times less effective against Staphylococcus epidermidis. Bioinorganic studies confirmed that upon incubation with human serum albumin, AF-AcCys, similarly to AF, induced protein metalation through the [AuPEt3]+ fragment. Additionally, AF-AcCys appeared capable of binding the dodecapeptide Ac-SGGDILQSGCUG-NH2, corresponding to the tryptic C-terminal fragment (488–499) of hTrxR. To shed light on the pharmacological differences between AF and AF-AcCys, we carried out a comparative experimental stability study and a theoretical estimation of bond dissociation energies, unveiling the higher strength of the Au–S bond in AF-AcCys. From the results, it emerged that the lower lipophilicity of AF-AcCys with respect to AF could be a key feature for its different antibacterial activity. The differences and similarities between AF and AF-AcCys are discussed, alongside the opportunities and consequences that chemical structure modifications imply.

2 November 2022 in Comments on Inorganic Chemistry
Verified
Journal Article
Closed access
Damiano CirriDamiano Cirri
Damiano Cirri
Lorenzo ChiaveriniLorenzo Chiaverini
Lorenzo Chiaverini
Alessandro PratesiAlessandro Pratesi
Alessandro Pratesi
Tiziano MarzoTiziano Marzo
Tiziano Marzo
Since the serendipitous discovery of cisplatin, thousands of inorganic molecules have been synthesized in search of new drugs endowed with powerful anticancer activity and safe profile. As matter of fact, this “magic” and desired combination to date remains unmet. On the other side, after cisplatin, only two additional platinum-based drugs -that have been substantially designed as cisplatin-like molecules- have been approved at the global level, i.e., carboplatin and oxaliplatin. Accordingly, here, we try to summarize and highlight some relevant reasons for this “lack” of newly approved molecules. Also, we try to rationalize what are the critical steps in the discovery process (and approval) of new ameliorated anticancer metallodrugs, contributing to stimulate an open and critical scientific debate. Graphical Abstract

Verified
Journal Article
Open access
PDF file
Lorenzo ChiaveriniLorenzo Chiaverini
Lorenzo Chiaverini
Damiano CirriDamiano Cirri
Damiano Cirri
Iogann TolbatovIogann Tolbatov
Iogann Tolbatov
FCFrancesca Corsi
Francesca Corsi
Ilaria PianoIlaria Piano
Ilaria Piano
DMDiego La Mendola
Diego La Mendola
Ammonium trichloro (dioxoethylene-O,O′) tellurate (AS101) is a potent immunomodulator prodrug that, in recent years, entered various clinical trials and was tested for a variety of potential therapeutic applications. It has been demonstrated that AS101 quickly activates in aqueous milieu, producing TeOCl3−, which likely represents the pharmacologically active species. Here we report on the study of the activation process of AS101 and of two its analogues. After the synthesis and characterization of AS101 and its derivatives, we have carried out a comparative study through a combined experimental and computational analysis. Based on the obtained results, we describe here, for the first time, the detailed reaction that AS101 and its bromido- and iodido-replaced analogues undergo in presence of water, allowing the conversion of the original molecule to the likely true pharmacophore. Interestingly, moving down in the halogens’ group we observed a higher tendency to react, attributable to the ligands’ effect. The chemical and mechanistic implications of these meaningful differences are discussed.

20 June 2023 in Dalton Transactions
Verified
Journal Article
Open access
PDF file
Giarita FerraroGiarita Ferraro
Giarita Ferraro
VSVanessa Sanfilippo
Vanessa Sanfilippo
Lorenzo ChiaveriniLorenzo Chiaverini
Lorenzo Chiaverini
Cristina SatrianoCristina Satriano
Cristina Satriano
Tiziano MarzoTiziano Marzo
Tiziano Marzo
DMDiego La Mendola
Diego La Mendola
The interaction between cisplatin and angiogenin, a protein strongly expressed in many types of cancer and a potent angiogenic factor, has been investigated.

28 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DGDoralice Giorgini
Doralice Giorgini
Lorenzo ChiaveriniLorenzo Chiaverini
Lorenzo Chiaverini
MVMonica Viviano
Monica Viviano
Raffaella BelvedereRaffaella Belvedere
Raffaella Belvedere
SSSilvia Salerno
Silvia Salerno
EBelisabetta barresi
elisabetta barresi
Auranofin (AF) is an oral gold(I) compound with a well-known pharmacological profile, currently used in the treatment of some severe forms of rheumatoid arthritis. Over the last twenty years, AF has also been repurposed as an antitumor, antiviral, and antibacterial drug. In this context, this review provides an updated overview of all clinical trials investigating AF for the treatment of various pathologies, either as monotherapy or in combination with other agents. We started summarizing the rationale behind repurposing AF in oncology, including its ability to inhibit thioredoxin reductase (TrxR) and disrupt redox homeostasis, leading to selective cytotoxicity in cancer cells. Clinical data from trials across a range of tumors are reviewed, highlighting safety profiles, dosing regimens, pharmacokinetics, and observed therapeutic outcomes. Then, we discussed the synergistic effects observed when AF is combined with chemotherapeutics, targeted therapies, or immune modulators. Then, an overview concerning the trials involving AF in non-oncological settings is also provided. Despite promising preclinical results, clinical translation remains in early stages, with most trials still in phase I or II. Nevertheless, emerging evidence supports continued exploration of AF-based therapies to address unmet medical needs.

23 January 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
CFCaterina Ferretti
Caterina Ferretti
Lorenzo ChiaveriniLorenzo Chiaverini
Lorenzo Chiaverini
NPNoemi Poma
Noemi Poma
ADAndrea Dalli
Andrea Dalli
Riccardo Di LeoRiccardo Di Leo
Riccardo Di Leo
MLMariagrazia Di Luca
Mariagrazia Di Luca
Background/Objectives: The ability of bacteria to form biofilms makes them more tolerant to traditional antibiotics. Given the lack of new antibiotic development, drug repurposing offers a strategy for discovering new treatments. Auranofin (AF), a gold-based compound indicated for the treatment of rheumatoid arthritis, shows promising antibacterial activity. This study investigates the antimicrobial and antibiofilm activity of AF and its two derivatives in which the thiosugar ligand is replaced by acetylcysteine (AF-AcCys) or naproxen (AF-Napx), against Staphylococcus aureus and Staphylococcus epidermidis. Methods: AF was conjugated by transmetalation with either naproxen or acetylcysteine. Assessments of their stability in DMSO/H2O and lipophilicity expressed as the LogP were performed. The antimicrobial activity of AF and its analogues were investigated by broth microdilution assay to determine the minimum inhibitory concentration (MIC) and versus biofilm to obtain the minimum bactericidal biofilm concentration (MBBC) and minimum biofilm eradication concentration (MBEC). Results: AF derivatives were found to be stable in a DMSO/H2O mixture for 48 h. AF-Napx showed a LogP = 1.25 ± 0.22, close to AF, while AF-AcCys had a LogP = −0.95. MIC values of S. aureus and S. epidermidis were ranging from 2 µM to 0.25 µM, and ≤0.12 µM, respectively. Both AF and AF-Napx maintained efficacy against biofilm-embedded S. aureus and S. epidermidis at non-cytotoxic concentrations, with AF-Napx demonstrating lower MBBC values for S. epidermidis. Conclusions: AF, and especially its naproxen conjugate, holds potential as a therapeutic agent for treating biofilm-associated infections caused by S. aureus and S. epidermidis, particularly in device-related infections where both infection and inflammation are present.